drugset / Trial / NCT00922792
Safety and Mode of Action of a Single Dose and Multiple Doses of Long Acting Activated Recombinant Human Factor VII in Patients With Haemophilia A and B
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This trial is conducted in Europe. The aim of this clinical trial is to investigate the safety and pharmacokinetics (the effect of the body on the investigated drug) of long acting activated recombinant human factor VII (LA-rFVIIa) in patients with haemophilia.
Timeline
- Start
- 2009-06
- Primary completion
- 2009-09
- Completion
- 2009-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | EPTACOG ALFA PEGOL (ACTIVATED) | Protein / enzyme biologic | 0.2 mg/kg | Intravenous |
| Subject | EPTACOG ALFA PEGOL (ACTIVATED) | Protein / enzyme biologic | 100 mg/kg | Intravenous |